Targeting Protein-Tyrosine Phosphatases in Breast Cancer
Targeting Protein-Tyrosine Phosphatases in Breast Cancer |
|
https://doi.org/10.18632/oncotarget.496
Nicola Aceto,
and Mohamed Bentires-Alj
|
| 514-515 |
Voltage-dependent K+ channels as oncotargets in malignant gliomas
Voltage-dependent K+ channels as oncotargets in malignant gliomas |
|
https://doi.org/10.18632/oncotarget.514
Florence Lefranc,
Henri-Benjamin Pouleau,
Michal Rynkowski,
and Olivier De Witte
|
| 516-517 |
A novel co-operative mechanism linking TGFβ and Lyn kinase activation to imatinib resistance in chronic myeloid leukaemia cells
A novel co-operative mechanism linking TGFβ and Lyn kinase activation to imatinib resistance in chronic myeloid leukaemia cells |
|
https://doi.org/10.18632/oncotarget.500
Andrew Chantry,
Paul G Smith,
and Hideo Tanaka
|
| 518-524 |
The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells
The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells |
|
https://doi.org/10.18632/oncotarget.491
Elisabeth J. Walsby,
Laurence Pearce,
Alan K. Burnett,
Chris Fegan,
and Chris Pepper
|
| 525-534 |
A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma.
A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma. |
|
https://doi.org/10.18632/oncotarget.498
Francesco Sottile,
Ilaria Gnemmi,
Sandra Cantilena,
Walter C. D'Acunto,
and Arturo Sala
|
| 535-545 |
Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil-DNA glycosylase.
Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil-DNA glycosylase. |
|
https://doi.org/10.18632/oncotarget.503
Hongdo Do,
and Alexander Dobrovic
|
| 546-558 |
Solid Tumor Differentiation Therapy – Is It Possible?
Solid Tumor Differentiation Therapy – Is It Possible? |
|
https://doi.org/10.18632/oncotarget.512
Filemon Dela cruz,
and Igor Matushansky
|
| 559-567 |
Novel Therapeutic Targets in the Brain Tumor Microenvironment
Novel Therapeutic Targets in the Brain Tumor Microenvironment |
|
https://doi.org/10.18632/oncotarget.526
Joanna J. Phillips
|
| 568-575 |
FLT3 in lineage specification and plasticity
FLT3 in lineage specification and plasticity |
|
https://doi.org/10.18632/oncotarget.499
Sarah Greenblatt,
and Donald Small
|
| 576-580 |
Cell-based high-throughput screens for the discovery of chemotherapeutic agents
Cell-based high-throughput screens for the discovery of chemotherapeutic agents |
|
https://doi.org/10.18632/oncotarget.513
Jennifer T Fox,
and Kyungiae Myung
|
| 581-585 |
Mantle cell lymphoma-like lymphomas in c-myc-3’RR/p53+/- mice and c-myc-3’RR/Cdk4R24C mice: differential oncogenic mechanisms but similar cellular origin
Mantle cell lymphoma-like lymphomas in c-myc-3’RR/p53+/- mice and c-myc-3’RR/Cdk4R24C mice: differential oncogenic mechanisms but similar cellular origin |
|
https://doi.org/10.18632/oncotarget.474
Pauline Rouaud,
Rémi Fiancette,
Christelle Vincent-Fabert,
Virginie Magnone,
Michel Cogné,
Pierre Dubus,
and Yves Denizot
|
| 586-593 |
